<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2448-8909</journal-id>
<journal-title><![CDATA[Medicina crítica (Colegio Mexicano de Medicina Crítica)]]></journal-title>
<abbrev-journal-title><![CDATA[Med. crít. (Col. Mex. Med. Crít.)]]></abbrev-journal-title>
<issn>2448-8909</issn>
<publisher>
<publisher-name><![CDATA[Colegio Mexicano de Medicina Crítica A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2448-89092016000200127</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Uso de inmunoglobulina en choque séptico. Estudio retrospectivo de cohorte en la Unidad de Terapia Intensiva del Hospital Ángeles Pedregal]]></article-title>
<article-title xml:lang="en"><![CDATA[Use of immununoglobulin in septic shock. A retrospective study of cohort in the Intensive Care Unit in the Hospital Ángeles Pedregal]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Enriquez Vidal]]></surname>
<given-names><![CDATA[Alejandro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hernández Cortés]]></surname>
<given-names><![CDATA[Christopher]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Carrillo Ramírez]]></surname>
<given-names><![CDATA[Silvia Del Carmen]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Esponda Prado]]></surname>
<given-names><![CDATA[Juan Gerardo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Ángeles Pedregal  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2016</year>
</pub-date>
<volume>30</volume>
<numero>2</numero>
<fpage>127</fpage>
<lpage>129</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2448-89092016000200127&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2448-89092016000200127&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2448-89092016000200127&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  Introducción: El uso de las inmunoglobulinas como tratamiento adyuvante en choque séptico llega a ser una opción terapéutica como inmunomodulador, además de presentar un mecanismo de bloqueo de la apoptosis.  Método: Se revisó de forma retrospectiva, expedientes con el diagnóstico de choque séptico a su ingreso a la Unidad de Terapia Intensiva, del 1 de agosto de 2014 al 31 de julio de 2015. Se integraron dos grupos uno con inmunoglobulina como coadyuvante. Se buscó medir la supervivencia por medio del método de Kaplan-Meier, con análisis de comparación de Mantel-Cox.  Resultados: El universo lo conformaron 18 pacientes con diagnóstico de choque séptico, distribuidos en dos grupos de nueve pacientes cada uno. El grupo 1 (inmunoglobulina): 22% de mortalidad con una mediana de 15 días en comparación con el grupo 2 (no inmunoglobulina): 55% de mortalidad con una mediana de ocho días, con una diferencia estadísticamente significativa (p = 0.004).  Conclusiones: Nuestro estudio mostró que hubo un aumento en la supervivencia en los pacientes que recibieron inmunoglobulina en comparación con aquellos que no. Sin embargo, se requieren de estudios prospectivos aleatorizados para recomendar su uso.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract:  Introduction:  The use of immunoglobulins as adjunctive therapy in septic shock becomes a therapeutic option as an immunomodulator, and as a blocking mechanism of apoptosis.  Method:  We reviewed retrospectively, patient&#8217;s charts with the diagnosis of septic shock on admission to the ICU, from August 1, 2014 to July 31, 2015. Two groups were formed, one with immunoglobulin as an adjuvant. We sought to measure the statistical survival through Kaplan-Meier analysis comparing its significance with Mantel-Cox.  Results:  The cohort was formed of 18 patients diagnosed with septic shock. Both groups were formed with 9 patients each. Group 1 (immunoglobulin): had a mortality of 22% with a median of survival of 15 days compared to the Group 2 (no immunoglobulin): mortality of 55% with a median of 8 days, with a statistically significant difference (p = 0.004).  Conclusions:  Our study showed that there was an increase in survival in patients receiving immunoglobulin compared to those without it. However, we believe that more prospective randomized trials should be made to recommend its use.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Inmunoglobulinas]]></kwd>
<kwd lng="es"><![CDATA[choque séptico]]></kwd>
<kwd lng="es"><![CDATA[inmunomodulación]]></kwd>
<kwd lng="en"><![CDATA[Immunoglobulin]]></kwd>
<kwd lng="en"><![CDATA[septic shock]]></kwd>
<kwd lng="en"><![CDATA[immunomodulation]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Loza-Vázquez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[León-Gil]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[León-Regidor]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nuevas alternativas terapéuticas para la sepsis grave en el paciente crítico]]></article-title>
<source><![CDATA[Med Intensiva]]></source>
<year>2011</year>
<volume>35</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>236-45</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Conlledo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Godoy]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Merino]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Globulinas totales y recuento linfocitario como marcadores de mortalidad en sepsis y shock séptico]]></article-title>
<source><![CDATA[Rev Chilena Infectol]]></source>
<year>2012</year>
<volume>29</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>192-9</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mogica-Martínez]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Uso terapéutico actual de la inmunoglobulina intravenosa]]></article-title>
<source><![CDATA[Rev Med Inst Mex Seguro Soc]]></source>
<year>2006</year>
<volume>44</volume>
<numero>Suppl 2</numero>
<issue>Suppl 2</issue>
<page-range>81-6</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Berrón]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Espinosa]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Márquez]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Sainos]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Marfil]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Selva]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Consenso de expertos en el uso terapéutico actual de la inmunoglobulina intravenosa]]></article-title>
<source><![CDATA[Rev Alerg Mex]]></source>
<year>2005</year>
<volume>52</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>42-50</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Salinas]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Fica]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inmunoglobulinas en sepsis y shock séptico]]></article-title>
<source><![CDATA[Rev Chil Infectol]]></source>
<year>2005</year>
<volume>22</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>21-31</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Montoya]]></surname>
<given-names><![CDATA[GCJ]]></given-names>
</name>
<name>
<surname><![CDATA[Sorensen]]></surname>
<given-names><![CDATA[RU]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lecciones sobre el uso de gamaglobulina humana endovenosa]]></article-title>
<source><![CDATA[Boletín LAGID]]></source>
<year>2001</year>
<volume>23</volume>
<page-range>971-1010</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ozcan]]></surname>
<given-names><![CDATA[PE]]></given-names>
</name>
<name>
<surname><![CDATA[Senturk]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Orhun]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Gumru]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Arican]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Orhan]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of intravenous immunoglobulin therapy on behavior deficits and functions in sepsis model]]></article-title>
<source><![CDATA[Ann Intensive Care]]></source>
<year>2015</year>
<volume>5</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>62</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Esen]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Senturk]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Ozcan]]></surname>
<given-names><![CDATA[PE]]></given-names>
</name>
<name>
<surname><![CDATA[Ahishali]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Arican]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Orhan]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intravenous immunoglobulins prevent the breakdown of the blood-brain barrier inexperimentally induced sepsis]]></article-title>
<source><![CDATA[Crit Care Med]]></source>
<year>2012</year>
<volume>40</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1214-20</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Capasso]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Borrelli]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Parrella]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Lama]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrara]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Coppola]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Are IgM-enriched immunoglobulins an effective adjuvant in septic VLBW infants]]></article-title>
<source><![CDATA[Ital J Pediatr]]></source>
<year>2013</year>
<volume>39</volume>
<page-range>63</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vincent]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Emerging therapies for the treatment of sepsis]]></article-title>
<source><![CDATA[Curr Opin Anaesthesiol]]></source>
<year>2015</year>
<volume>28</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>411-6</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nakamura]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Doi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Okamoto]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Arai]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ueha]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Matsushima]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Specific antibody in IV immunoglobulin for postsplenectomy sepsis]]></article-title>
<source><![CDATA[Crit Care Med]]></source>
<year>2013</year>
<volume>41</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>e163-70</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Toth]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Mikor]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Leiner]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Molnar]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Bogar]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Szakmany]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of IgM-enriched immunoglobulin therapy in septic-shock-induced multiple organ failure pilot study]]></article-title>
<source><![CDATA[J Anesth]]></source>
<year>2013</year>
<volume>27</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>618-22</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Soares]]></surname>
<given-names><![CDATA[MO]]></given-names>
</name>
<name>
<surname><![CDATA[Welton]]></surname>
<given-names><![CDATA[NJ]]></given-names>
</name>
<name>
<surname><![CDATA[Harrison]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Peura]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Shankar-Hari]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Harvey]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An evaluation of the feasibility, cost and value of information of a multicentre randomized controlled trial of intravenous immunoglobulin for sepsis (severe sepsis and septic shock) incorporating a systematic review, meta-analysis and value of information analysis]]></article-title>
<source><![CDATA[Health Technol Assess]]></source>
<year>2012</year>
<volume>16</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1-186</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Esen]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Tugrul]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[IgM-enriched Immunoglobulins in sepsis. (Chapter)]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Vincent]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<source><![CDATA[Intensive Care Medicine Annual Update]]></source>
<year>2009</year>
<page-range>102-10</page-range><publisher-loc><![CDATA[New York ]]></publisher-loc>
<publisher-name><![CDATA[Springer-Verlag]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Di Rosa]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Pietrosanti]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Luzi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Salemi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[D'Amelio]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Polyclonal intravenous immunoglobulin an important additional strategy in sepsis?]]></article-title>
<source><![CDATA[Eur J Intern Med]]></source>
<year>2014</year>
<volume>25</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>511-6</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Welte]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Dellinger]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
<name>
<surname><![CDATA[Ebelt]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Opal]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Schliephake]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Concept for a study design in patients with severe community-acquired pneumonia a randomized controlled trial with a novel IGM-enriched immunoglobulin preparation - The CIGMA study]]></article-title>
<source><![CDATA[Respir Med]]></source>
<year>2015</year>
<volume>109</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>758-67</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Almansa]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Tamayo]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Andaluz-Ojeda]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Nogales]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Blanco]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Eiros]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The original sins of clinical trials with intravenous immunoglobulins in sepsis]]></article-title>
<source><![CDATA[Crit Care]]></source>
<year>2015</year>
<volume>19</volume>
<page-range>90</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dellinger]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
<name>
<surname><![CDATA[Levy]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Rhodes]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Annane]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Gerlach]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Opal]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Surviving Sepsis Campaign international guidelines for management of severe sepsis and septic shock, 2012]]></article-title>
<source><![CDATA[Intensive Care Med]]></source>
<year>2013</year>
<volume>39</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>165-228</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moreno]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Vincent]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Matos]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Mendonça]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cantraine]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Thijs]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The use of maximum SOFA score to quantify organ dysfunction/failure in intensive care Results of a prospective, multicentre study. Working Group on Sepsis related Problems of the ESICM]]></article-title>
<source><![CDATA[Intensive Care Med]]></source>
<year>1999</year>
<volume>25</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>686-96</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Metnitz]]></surname>
<given-names><![CDATA[PG]]></given-names>
</name>
<name>
<surname><![CDATA[Moreno]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
<name>
<surname><![CDATA[Almeida]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Jordan]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Bauer]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Campos]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[From evaluation of the patient to evaluation of the intensive care unit Part 1: objectives, methods and cohort description]]></article-title>
<source><![CDATA[Intensive Care Med]]></source>
<year>2005</year>
<volume>31</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1336-44</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Metnitz]]></surname>
<given-names><![CDATA[PG]]></given-names>
</name>
<name>
<surname><![CDATA[Moreno]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
<name>
<surname><![CDATA[Almeida]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Jordan]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Bauer]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Campos]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[SAPS 3-From evaluation of the patient to evaluation of the intensive care unit Part 2: development of a prognostic model for hospital mortality at ICU admission]]></article-title>
<source><![CDATA[Intensive Care Med]]></source>
<year>2005</year>
<volume>31</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1345-55</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
